—
C+
C+ The full Closelooknet — membership. Open the C+ overview

CG Oncology, Inc. Common stock (CGON) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for CGON, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 57/100 · S&P 500 fund at 71, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-10-09
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 94th percentile of the window, +5.0% over 20 sessions. Factor regime → 2026-10-12
  • Sector × region Health care in US: +2.8% week · +3.5% month · +6.2% quarter · +17.8% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-10-11
  • Sovereign pressure Index 0.04 · down 0.71 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-10-09
How it trades on rate days beta 1.08 to TLT · on the worst bond days it fell more than the market

How it trades on rate days

How CGON has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 1.08 — moves strongly with bonds for every 1% move in TLT (20+ year Treasuries), CG Oncology, Inc. Common stock moved 1.08% on average · correlation 0.18 · higher than 89% of US names
  • Beta, last 3 months 1.73 more rate-sensitive lately than over the year
  • On the 10 worst bond days −2.59% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days −6.27% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

Names in the same industry from the Closelooknet universe; scored names rank on their Closelooknet score, the rest on trend state.

Compared against CGON on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — CG Oncology, Inc. Common stock

CGON in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
CG Oncology develops cretostimogene, an experimental virus-based immunotherapy that trains the immune system to attack bladder tumours after standard BCG treatment fails. The company runs several late-stage trials testing the therapy alone in different bladder-cancer stages, from high-risk disease to intermediate-risk cases after surgery. It has no approved product yet and generates no product revenue, relying on trial data to support future approval filings. It is based in Dallas and listed in New York.
Where it sits in the stack
CG Oncology carries no seat in Rubin, our AI-buildout index, and none in Halo; it sits outside the AI stack entirely. In our universe it belongs to the Healthcare/Biotechnology sleeve, where the diary follows clinical-stage names on trial catalysts rather than build-out exposure.
Who it is priced against
Closelooknet has not set a peer group for this name; the comparison the market draws is with other bladder-cancer immunotherapy developers working on alternatives to standard BCG treatment.
Why Closelooknet tracks it
CG Oncology holds no Rubin or Halo seat and carries no Closelooknet score, so no module can be named as strongest or weakest. It appears in the diary only as an occasional single-name entry, without editions or quotes tied to it.
What the diary watches
Whether upcoming trial readouts for cretostimogene, across its bladder-cancer studies, shift the stock enough to justify closer coverage.

CG Oncology, Inc. Common stock (CGON) trades on US exchanges, classified under Healthcare.

The Closelooknet company score reads 41/100 composite (momentum 44, quality 2, valuation 5) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Dividends and capital return no distribution in twelve months

Dividends and capital return

What CGON pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Share count +23.7% in FY2025 27 m USD of stock-based compensation in the year

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-10-13

Quick answers

What is CG Oncology, Inc. Common stock (CGON)?

CG Oncology, Inc. Common stock trades as CGON on the US exchange (US) and is classified under Healthcare in the Closelooknet research universe, as of the registry build of 2026-10-13.

Is CGON in a Closelooknet index?

Not currently — CG Oncology, Inc. Common stock is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-10-13.

What is CG Oncology, Inc. Common stock's Closelooknet composite score?

41 out of 100, with momentum 44, quality 2 and valuation 5 sub-scores, as of 2026-10-13. Scores are Closelooknet's own research readings, not ratings or investment advice.

Where does CGON trade against its moving averages?

Mixed moving-average stack: Trades -13.7% vs the 50-day and -2.4% vs the 200-day average, 22% below the 52-week high and +76.3% off the 52-week low. Computed from daily closes. As of 2026-10-12 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does CG Oncology, Inc. Common stock compare with its peers?

Against its peer group (Biotechnology · US), CG Oncology, Inc. Common stock (CGON) sits 22.0% below its 52-week high, 13.7% below its 50-day average; Halozyme Therapeutics Inc (HALO) is 4.9% below, BeiGene, Ltd. (ONC) is 9.0% below, argenx NV ADR (ARGX) is 24.3% below. Put any of them next to CGON in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

How does CG Oncology, Inc. Common stock trade when bond yields rise?

Over the past year CG Oncology, Inc. Common stock had a beta of 1.08 to TLT, the long-dated Treasury fund — it moves strongly with bonds, higher than 89% of US names. On the 10 sessions in which long bonds fell most it moved −2.59% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

What does CG Oncology, Inc. Common stock do?

CG Oncology develops cretostimogene, an experimental virus-based immunotherapy that trains the immune system to attack bladder tumours after standard BCG treatment fails. The company runs several late-stage trials testing the therapy alone in different bladder-cancer stages, from high-risk disease to intermediate-risk cases after surgery. It has no approved product yet and generates no product revenue, relying on trial data to support future approval filings. Closelooknet has not set a peer group for this name; the comparison the market draws is with other bladder-cancer immunotherapy developers working on alternatives to standard BCG treatment.

Where does CG Oncology, Inc. Common stock sit in the AI build-out?

CG Oncology carries no seat in Rubin, our AI-buildout index, and none in Halo; it sits outside the AI stack entirely. In our universe it belongs to the Healthcare/Biotechnology sleeve, where the diary follows clinical-stage names on trial catalysts rather than build-out exposure. CG Oncology holds no Rubin or Halo seat and carries no Closelooknet score, so no module can be named as strongest or weakest. It appears in the diary only as an occasional single-name entry, without editions or quotes tied to it.

Does CG Oncology, Inc. Common stock pay a dividend?

No cash distribution shows in CG Oncology, Inc. Common stock’s price series over the last three years. The share count rose 23.7% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What does this page show?

A live price chart with SMA overlays and drawing tools for CGON, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.